Danaher’s valuation narrative has been nudged higher, with the fair value estimate edging up to about $255.67 from roughly $254.20 as analysts refine their long term growth and risk assumptions. While the discount rate has ticked up to around 8.00% and revenue growth expectations have slipped only marginally to nearly 5.47%, the Street’s tone has shifted to a more balanced, wait and see stance amid slower near term recovery in key end markets. Stay tuned to see how to track these subtle yet meaningful shifts in expectations as the Danaher story continues to evolve.

Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Danaher.

???? Bullish Takeaways

BofA maintains a Buy rating with a revised price target of $220, signaling confidence that Danaher can navigate lingering softness in Life Sciences and Diagnostic Tools as conditions gradually normalize.

Bullish analysts at BofA continue to reward Danaher for its execution and cost discipline, suggesting the company is well positioned to benefit once demand trends move closer to historical growth patterns.

Even with trimmed forecasts at BofA, the stock is still viewed as offering upside over time, though near term valuation and ongoing end market uncertainty temper enthusiasm.

???? Bearish Takeaways

Rothschild & Co Redburn downgraded Danaher to Neutral from Buy and cut its price target to $220 from $245, arguing that the current premium valuation already discounts a return to historical life science growth.

Rothschild flags limited visibility into the pace of recovery in China and questions the sustainability of diagnostics growth, leading the firm to see constrained upside to current estimates and a more balanced risk reward profile.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

Issued updated guidance calling for low single digit core revenue growth in Q4 2025 and core revenue growth of 3% to 6% for full year 2026, assuming a modest recovery across key end markets.

Announced a new share repurchase program authorizing the buyback of up to 35,000,000 common shares with no expiration date, intended to support equity compensation plans and broader corporate capital allocation priorities.

Disclosed that between June 28, 2025 and September 26, 2025 it repurchased 10,000,000 shares for approximately $2.01 billion, bringing total buybacks under the July 23, 2024 authorization to 18,000,000 shares for about $3.9 billion.

Amended and restated its bylaws effective September 9, 2025, tightening advance notice, procedural, and disclosure requirements for shareholder proposals and director nominations, and making additional routine corporate governance updates.

The fair value estimate has risen slightly to approximately $255.67 from about $254.20, reflecting a modest upward adjustment in long term assumptions.

The discount rate has increased marginally to about 8% from roughly 7.97%, implying a slightly higher required return embedded in the valuation model.

Revenue growth has edged down fractionally to around 5.47% from about 5.48%, indicating a nearly unchanged outlook for top line expansion.

The net profit margin has increased insignificantly to approximately 21.76% from about 21.76%, signaling a virtually flat profitability profile in the updated forecast.

The future P/E multiple has risen slightly to roughly 35.4x from about 35.2x, suggesting a small uptick in the valuation placed on projected earnings.

Narratives are investor written stories that connect Danaher’s business reality to the numbers, linking a clear thesis about its markets, strategy, and risks to specific forecasts for revenue, earnings, and margins, and ultimately to a fair value. On Simply Wall St’s Community, millions of investors use Narratives as an easy, dynamic tool that updates as news and earnings land, helping them compare fair value to the current share price.

Head over to the Simply Wall St Community and follow the Narrative on Danaher to stay on top of how this story evolves, including:

Why strong recurring revenue, innovation in precision medicine, and the Danaher Business System may justify a premium multiple even as recovery remains gradual.

How share repurchases, margin expansion, and forecasts for EPS growth to an expected $8.12 by 2028 are being used within the Narrative.

What risks in China, biotech funding, and bioprocessing demand might affect the thesis if growth or policy trends move against Danaher.

Read the full Danaher Narrative and track every update in real time.

Curious how numbers become stories that shape markets? Explore Community Narratives

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include DHR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com